Pharmaceutical Good Manufacturing Practice Regulations Article 121
Manufacturers shall identify and implement any changes necessary to ensure and maintain the continued suitability and effectiveness of the quality management system through the use of the quality policy, quality objectives, audit results, analysis of data, corrective and preventive actions and management review.Manufacturers shall establish documented procedures for the issue and implementation of advisory notices. These procedures shall be capable of being implemented at any time.Manufacturers shall maintain the records of all customer complaint investigations. If investigation determines that the activities outside the manufacturers contributed to the customer complaint, relevant information shall be exchanged between the organizations involved.If any customer complaint is not followed by corrective and/or preventive action, manufacturers shall authorize and record the reason.Manufacturers shall establish reporting procedures in accordance with the regulations of central competent health authority for the notification of adverse events or recall actions to the central competent health authority or its designated organization.
中文原文 藥物優良製造準則第121條
製造業者應利用品質政策、品質目標、稽核結果、資料分析、預防與矯正措施及管理審查來鑑別與實施任何必要之變更,以確保並持續維持品質管理系統之適當性與有效性。
製造業者應建立說明事項之發布與實施之書面程序,並應能隨時實施該程序。
製造業者應維持所有顧客申訴調查之紀錄。
如經調查結果確定顧客申訴並非由製造業者之活動所導致,應向相關單位揭示相關資料。
任何未採取預防與(或)矯正措施之顧客申訴,製造業者應核可並記錄其理由。
製造業者應依中央衛生主管機關規定,訂定醫療器材不良反應事件或回收作業,向中央衛生主管機關或其委託機構之通報程序。
製造業者應建立說明事項之發布與實施之書面程序,並應能隨時實施該程序。
製造業者應維持所有顧客申訴調查之紀錄。
如經調查結果確定顧客申訴並非由製造業者之活動所導致,應向相關單位揭示相關資料。
任何未採取預防與(或)矯正措施之顧客申訴,製造業者應核可並記錄其理由。
製造業者應依中央衛生主管機關規定,訂定醫療器材不良反應事件或回收作業,向中央衛生主管機關或其委託機構之通報程序。